Of note, the bioinformatics analysis indicated elevated ZNF300 expression in other highly aggressive tumor types, including anaplastic oligodendroglioma, glioblastoma, skin basal cell carcinoma, and invasive breast carcinomas (Figure 4). This evidence concerns the gene ZNF300 and neoplasm.